PETER MANSBRIDGE: These little blue pills are usually prescribed to treat a grown-up problem. But one Canadian doctor has started giving Viagra to children to try to treat an often fatal lung disorder. The CBC's health reporter Maureen Taylor has the details.
MAUREEN TAYLOR (Reporter): Quinlan O'Blenis is only seven, but next month he is going to start taking Viagra in a clinical trial. Quinlan has pulmonary hypertension. Dr. Ian Adatia is the first Canadian doctor to experiment with Viagra in children with this disorder.
DR. IAN ADATIA (Toronto's Hospital for Sick Children): We knew that mechanisms that might be applicable in the penis might be useful in treating pulmonary hypertension.
TAYLOR: Pulmonary hypertension is a rare disorder where the lung arteries narrow and thicken. Most patients die of heart failure within a few years of diagnosis. Viagra, which was originally developed to treat angina in the heart, relaxes blood vessels and arteries. In people with pulmonary hypertension, Viagra improves blood flow to the heart. Quinlan's mother hopes Viagara will mean the end of IVs and catheters.
TRACEY O'BLENIS (Quinlan's Mother): It is taken orally so it is, of course, much easier. The things that he can't do as far as swimming and he would be able to do.
TAYLOR: Dr. Adatia got permission from Toronto's Hospital for Sick Children to treat sixteen young patients with Viagra. Nine of them have responded well. The drug has never undergone large clinical trials for pulmonary hypertension, and it's only been tested in a handful of children worldwide. But doctors like Stephen Archer, who has used Viagra in adults with pulmonary hypertension, say what they're doing is not controversial.
DR. STEPHEN ARCHER (University of Alberta): For science and medicine to move forward you have to take risk in a controlled environment where people have given informed consent.
ADATIA: It is one of the most exciting therapies of my career for a group of children that have such a poor prognosis.
TAYLOR: Doctors don't expect Viagra to cure pulmonary hypertension, but they're hoping it works at least as well as the present therapies and provides patients with a better quality of life. But only clinical trials, like the one Quinlan will be in, will tell us exactly how well it works and what the side effects might be. Maureen Taylor, CBC News, Toronto.
MANSBRIDGE: Now the clinical trial that Quinlan will take part in is in New York but large-scale clinical trials could begin in Canada within the year.
|